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Abstract
Background: The efficacy of a single dose of an inactivated bovine respiratory syncytial virus (BRSV) -
Parainfluenaza type 3 (PI3) - Mannheimia haemolytica (Mh) combination vaccine, in calves positive for maternal
antibodies, was established in a BRSV infection study.
Results: As expected the single vaccination did not have any effect on the decline of BRSV-specific neutralising or
ELISA antibody. The cellular immune system was however primed by the vaccination. In the vaccinated group virus
excretion with nasal discharge was reduced, less virus could be re-isolated from lung tissues and the lungs were
less affected.
Conclusions: These results indicate that a single vaccination with an inactivated BRSV vaccine was able to break
through the maternal immunity and induce partial protection in very young calves. It can be speculated that the
level and duration of protection will improve after the second dose of vaccine is administered. A two-dose basic
vaccination schedule is recommended under field conditions.
Background
The bovine respiratory syncytial virus (BRSV) has been
established as an important viral component in the
bovine respiratory disease complex (BRDC) [1]. The
virus can act synergistically with other viruses such as
the bovine parainfluenza type 3 virus (PI3) or bacteria
such as Mannheimia haemolytica (Mh), Pasteurella
multocida, Haemophilus somnus and Mycoplasma bovis
to cause pneumonia [2]. BRSV also fulfils the Koch’s
postulates to be recognised as an aetiological agent of
pneumonia in calves. Respiratory disease is however
often milder under laboratory conditions than under
field conditions [3-6].
Outbreaks of BRSV associated pneumonia typically
recur every year [7] and most farms are affected. The
mechanisms for the persistence of the virus in a farm
are not well understood [8]. Based on sequence
divergence among BRSV isolated during recurrent out-
breaks in closed herds, (re)introduction of the virus into
the herd prior to each new outbreak is the most likely
explanation [9]. Airborne transmission of BRSV has
been demonstrated under experimental conditions [10].
Different approaches have been followed to develop
safe and efficacious BRSV vaccines including inactivated
vaccines [11,12], (genetically) modified live vaccines
[11,13], subunit vaccines [14], DNA vaccines [15] and
vector vaccines [16,17]. Today inactivated and modified
live BRSV vaccines are commercially available, most of
them as combination vaccine with other antigens related
to the BRDC.
The basic vaccination schedule for inactivated BRSV
vaccines consist of two doses of 5 ml each, applied by
subcutaneous injections, at an interval of 3 to 4 weeks.
Remarkably most cases of severe BRSV are observed in
calves aged 1-3 months, at which time they still possess
maternal antibodies [18]. In order to provide efficacious
protection against BRSV at this very young age it is
essential that vaccines are able to overcome the
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tion shortly after vaccination. Due to the high risk of
BRSV associated pneumonia in the very young age
group, it is also of great value to evaluate the level of
immunity induced by the first vaccination before com-
pletion of the full primary course has taken place. The
inactivated BRSV-PI3-Mh combination vaccine used in
the study reported here has previously been shown to
reduce the severity of clinical signs and virus shedding
in two week-old MDA (+) calves that had received a pri-
mary course of two vaccinations four weeks apart. The
calves were challenged with BRSV 3 weeks after the sec-
ond vaccination. Moreover, in a previous study with the
same vaccine, the efficacy in terms of antibody response
and clinical protection has been established after appli-
c a t i o no fas i n g l ed o s eo ft h ev a c c i n et o4 - 5w e e ko l d
calves with maternal antibodies [19]. In the study
reported here two week old calves with maternal antibo-
dies were vaccinated with a single dose, antibody levels
as well as cellular immunity was measured. As it was
expected that the maternal antibodies would interfere
with the induction of clinical signs, lung pathology was
used as a parameter to evaluate protection.
Methods
Animals
Ten Holstein crossbred calves were included in the
study. They were removed from the dam directly after
birth in order to prevent infection with BRSV or other
pathogens. The calves were fed pre-collected colostrums
with high antibody titres against BRSV in order to
obtain similar antibody titres in all calves. The animals
were identified by means of numbered ear tags. They
were ranked by age and then allocated, on an alternating
basis, to one of the two treatment groups in order to
obtain the same average age for both groups. The com-
plete study was undertaken in a blinded manner.
From the week before vaccination and onwards the
calves were housed, separated by group, in two different
rooms of an isolation unit. Strict barrier conditions
between the two groups were maintained by means of
individual filtered air supply to each room, sealed doors
and by staff changing cloths and showering between the
rooms.
One calf allocated to the control group had to be
euthanised because of a persistent inflammation of the
carpal joint before challenge.
All procedures were approved upfront by the Animal
Care and Use Committee according to the Dutch animal
welfare regulations.
Vaccination
A commercial batch of an inactivated combined BRSV,
PI3 and Mh vaccine with alhydrogel and Quil A as adju-
v a n t s( B o v i l i sB o v i p a s tR S P ,I n t e r v e t / S c h e r i n g - P l o u g h
Animal Health) was used. Five calves were given a single
dose of 5 ml by the subcutaneous route into the neck. A
second group of 5 calves was not vaccinated. The aver-
age age of the calves at the time of vaccination was two
weeks.
Challenge
Four weeks after they had been vaccinated, all calves
were challenged by aerosolisation with a wild-type strain
of BRSV (CA-1, kindly provided by L. Gershwin) as
described earlier [13]. The challenge dose was 10
5.9
TCID50 in a 10 ml volume.
Assessment of clinical signs
From two days prior to challenge until the end of the
study the calves were observed daily for clinical reac-
tions and the body temperature was recorded. Special
attention was paid to signs of respiratory disease such as
coughing - spontaneous and stimulated (by palpation of
the larynx), nasal or ocular discharge and respiratory
rate.
Serology
To determine the calves’ antibody response to vaccina-
tion and challenge, blood samples were taken at vacci-
nation (day 0), just before challenge (day 28) and one
week later (day 35). Serum samples were assayed for
BRSV specific antibody by serum neutralising (VN) anti-
body and ELISA antibody.
The VN test was performed according to the end
point dilution method in a microtitre format. Two-fold
serial dilutions of the serum samples were incubated
with a fixed amount of BRSV prior to the addition of
Vero cells. After 5-7 days of culture, the plates were
read for BRSV specific cytopathic effects. The VN titres
were the reciprocal value of the highest dilution in
which complete neutralisation of the virus was obtained.
They were expressed as log2.
An in-house BRSV blocking ELISA was performed.
Plates were first coated with a BRSV specific monoclo-
nal antibody and secondly with BRSV antigen. After
appropriate washing steps, dilution series of the sera
were incubated followed by the incubation of a second
biotinylated monoclonal antibody. Avidin-peroxidase
complexes were allowed to bind to the biotin. A stan-
dard colour reaction using 3,3’;5,5’tetramethylbenzidine
as substrate was performed to quantitate the amount of
bound second antibody. Antibody titres were calculated
from the blocking percentage.
Cellular immune response
A lymphocyte activation assay was performed on hepari-
nised blood samples taken at days 0, 28 and 35. In 24-
well plates heparinised blood samples (sample volume: 1
ml) were stimulated with Concanavalin A (Sigma
Aldrich, 100 μl/ml blood) or lysate of BRSV infected
MDBK cells. Negative control samples were treated
similarly with culture medium or lysate of uninfected
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feron g (IFN g) production was measured using a com-
mercial ELISA (Bovine IFN g EASIA, Biosource Europe
S.A.) according to the manufacturer’s recommendations.
Nasal shedding of challenge virus
From two days prior to challenge until the end of the
study nasal swab samples were taken daily from all
calves by means of swab sticks containing a sterile cot-
ton plug. Separate swabs were used for each animal.
The swabs were gently rotated up and down the sides of
both nasal cavities several times. The swabs were then
inserted into a tube containing 1 ml of sterile phosphate
buffered saline medium. The liquid was transferred into
suitable containers and stored at temperatures below
-70°C until tested.
Post mortem examination
At seven or 10 days after challenge the calves were
sacrificed. The lungs were inspected macroscopically
and representative samples of organs showing any
changes were taken. The samples were fixed with forma-
lin and then processed into paraffin embedded sections.
These were stained with haematoxylin and eosin and
investigated microscopically.
Additional samples for virus isolation were taken from
nasopharyngeal mucosa, tonsils, submandibular lymph
nodes, each lung lobe and mediastinal and bronchial
lymph nodes.
Tracheobroncheal lung washes were performed as fol-
lows. Both lungs were excised and flushed with 300 ml
of saline. The liquid was recovered and stored at tem-
peratures below -70°C until tested.
Titration of nasal swab samples and lung wash fluid for
BRSV
The BRSV titre in nasal swab samples and lung wash
fluid was determined according to the end point dilution
method in a microtitre format. Five-fold serial dilutions
of the samples were incubated on bovine embryo lung
cells. Infection was evaluated by the development of
BRSV specific cytopathic effects after 5-7 days of cul-
ture. Each sample was tested in quadruplicates.
Testing of tissue samples for BRSV
Homogenized samples were incubated in four-fold on a
monolayer of Vero cells in 24-well plates. After 5-7 days
of culture supernatants of the cultures were transferred
onto fresh monolayers of Vero cells. The monolayers
after the first and the second passage were read for
BRSV specific cytopathic effects.
Statistical evaluation
The results were summarised using frequency tables.
The Wilcoxon two-sample test was performed to com-
pare: maximum titres in nasal swab samples, days of
virus excretion and extinction values in the INFg ELISA.
The above statistical tests were performed at 5% level
of significance. The data analysis was done using SAS
software, Version 8.2. Copyright
© [1999-2001] by SAS
Institute Inc., Cary, NC, USA.
Results
Clinical signs and body temperatures
Only minor clinical signs were observed. There were no
increased respiratory rates; in fact the only clinical sign
of respiratory disease was coughing of individual ani-
mals. One vaccinated animal showed stimulated cough-
ing, during examination, at 6 and 7 days after challenge.
Another vaccinated and one unvaccinated animal
coughed spontaneously on days 8 through 10.
Throughout the experiment none of the calves devel-
oped a fever (body temperature above 39.5°C).
BRSV specific immune reaction
BRSV specific antibody response
All calves had moderate to high antibody titres at the
start of the study (individual data not shown). The aver-
age VN and ELISA antibody titres at the time of vacci-
nation in the vaccinated group were 9.6 log2 and 8.2
log2 (see table 1). These values are very similar to the
average titres measured at the same time for the control
animals (9.3 log2 and 8.3 log2 for VN and ELISA respec-
tively). At the time of challenge (t = 28 days) and one
week later (t = 35 days) the titres were at the same level
or had dropped slightly for both groups.
BRSV specific cellular immune response
No cellular immune response, as determined in the lym-
phocyte stimulation assay, was detected at the time of
vaccination (see table 2). At the time of challenge one
out of five vaccinated animals were positive, all unvacci-
nated animals were negative.
One week after the challenge IFN g production was
measured in stimulated blood samples of four out of
five vaccinated and one out of four unvaccinated control
calves. The difference between the two groups was sta-
tistically significant (p < 0.05, Wilcoxon two-sample
test).
Virus re-isolation from nasal swab samples
From day 4 to day 7 after infection BRSV could be re-
isolated from nasal swab samples from three out of four
unvaccinated animals. (table 3). Only two out of five
vaccinated animals shed detectable but low levels of
Table 1 BRSV specific humoral immune response after
vaccination and challenge
Parameter VN antibody ELISA antibody
Time [days]◆ 0 2 83 50 2 8 3 5
Treatment group:
Vaccinated 9.6 8.0 7.6 8.2 6.5 6.5
Unvaccinated 9.3 8.4 7.5 8.3 6.6 6.5
◆ Calves were infected intranasally with live BRSV 28 days after vaccination
with one dose of the inactivated BRSV-PI3-Mh combination vaccine.
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maximum titres and the number of days when virus was
excreted was significantly lower in the vaccinated group
as compared to the control group (p < 0.05, Wilcoxon
two sample test.)
Gross and microscopic pathology findings
Macroscopic pathological findings differed substantially
between the animals No lung lesions were observed in
the lungs of two vaccinated and one unvaccinated ani-
mal. Only minor lesions were present in the lungs of
two vaccinated and two unvaccinated animals.
The lung of the fifth vaccinated animal showed dark
red consolidation of 10-25% of the medial and apical
lung lobes. In contrast all lung lobes of the fourth
unvaccinated animal were affected and 50% of the right
apical lobe and 80% of the medial lobe were
consolidated.
BRSV non-specific microscopic lesions were present in
two vaccinated and three control animals. Syncytial
cells, which are characteristic for BRSV infection, were
present in two vaccinated animals and suspected in one
control animal.
Isolation of BRSV from tissue samples and lung wash
fluid
BRSV could be re-isolated from tissue samples out of
the respiratory tract in four out of five vaccinated and
all unvaccinated animals (see table 4). The number of
positive samples was higher in the unvaccinated group
(average 4.5) than in the vaccinated (2.0).
The lung wash fluid of one vaccinated and one unvac-
cinated animal, both killed 7 days after infection, was
found positive for BRSV. All other samples were
negative.
Discussion
The clinical signs observed after intranasal challenge
with virulent BRSV were rather mild in the control ani-
mals and therefore no conclusion on clinical protection
can be drawn from this study. The difficulty of reprodu-
cing BRSV associated disease under experimental condi-
tions has been reported previously [3-6]. In the study
reported here calves with maternally derived antibodies
were used and the challenge was performed as early as
6 weeks of age. At that point maternal antibody levels
were still moderate to high. These maternal antibodies
are likely to interfere with the BRSV infection as
reported by Kimman and colleagues [18]. For this rea-
son BRSV vaccination-challenge studies reported in the
literature were often either performed in older animals
[19,20] or colostrum deprived calves [21]. or the
Table 3 Individual BRSV infection titres [log10TCID50] in nasal swab samples in vaccinated and control calves after
intranasal challenge with live BRSV
Treatment group Animal Days after infection
0123 4567891 0
Vaccinated V1 ---- - - - -n.s. n.s. n.s.
V 2 ---- - -2 . 7-n.s. n.s. n.s.
V 3 ---- - - - -n.s. n.s. n.s.
V 4 ---- - -2 . 0- - - -
V 5 ---- - - - - - - -
Control C1 ---- - - - -n.s. n.s. n.s.
C 2 ---- -2 . 0 3 . 9 2 . 0 n.s. n.s. n.s.
C 3 ---- - -3 . 6 3 . 43 . 6 - -
C 4 ----3 . 2-3 . 8- - - -
-: sample negative (titre below detection limit of 2.0 log10TCID50 /ml)
n.s. no sample (animal sacrificed 7 days after infection)
Table 2 BRSV specific cellular immune response
(extinction values of IFN g ELISA on stimulated whole
blood samples after vaccination and challenge)
Time [days]◆: 0 28 35
Treatment
group
Animal
Vaccinated V1 0.057* 0.185 0.736
V2 0.056 0.267 0.476
V3 0.054 0.223
V4 0.051 0.121 0.542
V5 0.052 0.054 0.408
Average
# 0.054
a 0.157
a 0.477
a
Unvaccinated C1 0.055 0.059 0.099
C2 0.052 0.060 0.214
C3 0.056 0.055 0.106
C4 0.057 0.060 0.067
Average 0.055
a 0.059
a 0.121
b
◆ Calves were infected intranasally with live BRSV 28 days after vaccination
with one dose of the inactivated BRSV-PI3-Mh combination vaccine.
*According to the information of the manufacturer of the assay, values above
the cut-off level (0.207) have to be interpreted as positive - indicated by the
bold letter type
# Average values with different superscript letters are significantly different (p
< 0.05) from each other.
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alternatively a combination of these different approaches
was applied. However an early challenge of young calves
with moderate to high maternally derived immunity, as
described in this study, reflects the field situation. Under
these conditions it is very difficult but also very impor-
tant for a BRSV vaccine to provide protection.
The vaccinated animals did not develop clinical signs
other than provoked or spontaneous coughing in one
animal. This observation is noteworthy since vaccine
induced exacerbation of BRSV infections has been
reported from field observations [24] and reproduced in
the laboratory [25]. The pathophysiology of the disease
in cattle was related to formalin inactivated BRSV. This
is analogous to reports on human RSV enhancement
after vaccination with formalin-inactivated RSV vaccine.
The hypothesis is however not in line with the results of
Mohanty and co-workers [26]. The vaccine used in this
study also contained formalin-inactivated BRSV. The
number of animals used here might be too low to allow
general conclusions, however our results confirm earlier
findings from laboratory studies [12,19] and unpublished
field data that the vaccine does not enhance BRSV dis-
ease severity in naturally infected cattle.
In this experiment a single dose of the inactivated
BRSV-PI3-Mh combination vaccine did not have any
effect on the decline of BRSV-specific neutralising or
ELISA antibody. This result was expected and is in line
with other reports [19,20]. The role of different types of
antibodies in protection against BRSV has been dis-
cussed in the literature [27]. Therefore, in this study,
VN titres and ELISA titres were determined. However
both types of antibody titres, VN and ELISA, followed
the same profile e.g. animals with high VN titres also
had high ELISA titres and vice versa. This finding indi-
cates that the colostrums used to feed the calves were
obtained from mothers with a similar history of BRSV
vaccination and/or infection.
Earlier studies with the same vaccine have shown a
clear booster response when the animals were given a
second dose of vaccine [20] or infected with BRSV 3
weeks after a single dose of the vaccine [19]. In this
study calves were euthanised for post mortem examina-
tion at 7 or 10 days post infection, therefore no booster
antibody response could be detected but it can be
speculated that the animals would have reacted with a
booster response.
A very interesting result in this study was the priming
of the cellular immune response by a single dose of vac-
cine in the absence of a measurable antibody response.
Kerkhofs and colleagues [20] also reported that the cel-
lular immune response, determined by lymphoprolifera-
tion, was induced by the same inactivated BRSV
vaccine. When discussed in the literature, the role of
CD8 cells in BRSV infection is very controversial. While
it has been reported that CD8 responses of animals vac-
cinated with a different inactivated BRSV vaccine did
not protect against immunopathology [28], these
immune cells seem to play a key role in the control of
i n f e c t i o ni nc a l v e s[ 2 9 ] .T h i si sc o n s i s t e n tw i t ht h e
reduction of virus excretion with nasal discharge in vac-
cinated animals when compared to control animals in
the study reported here. This result can be considered a
key finding in the study, as a reduction in the excretion
of challenge virus i) reflects the replication of the virus
indicating that the vaccine is protective and ii) is of
practical relevance because reduced virus shedding will
also limit the risk of infection for in-contact animals.
Post mortem examinations were performed on two
different days (7 or 10 days after infection) as it was
expected that hardly any BRSV virus would be detect-
able more than 1 week after infection, while lung
pathology would typically develop around 10 days after
infection. In general the results of BRSV re-isolation and
lung pathology in this study were in line with these
expectations.
BRSV was re-isolated from samples of different organs
from the respiratory tract of all control animals and
from four out of five vaccinated animals. The overall
number of positive samples was lower in the vaccinated
group indicating that BRSV replication was reduced
after vaccination.
This observation was also reflected by the lung pathol-
ogy. Macroscopic and histological findings in vaccinated
animals were minor and not comparable with the find-
ings in lung sections of BRSV infected unvaccinated ani-
m a l s .F r o mt h er e s u l t so b t a i n e di tc a n n o tb ee x c l u d e d
that other pathogenic agents like Mh were also involved.
The vaccine also contains Mh antigen and therefore also
protects against this pathogen.
Table 4 BRSV isolation from tissue samples and lung
wash fluid of vaccinated and control animals after
intranasal infection with BRSV
Treatment
group
Animal Post
mortem
on dpi
a
Number
tissue
sample
BRSV titre in lung
wash log10 TCID50/
ml
Vaccinated V1 7 1 -
V2 7 5 -
V3 7 0 4.5
V4 10 1 -
V5 10 3 -
Control C1 7 6 -
C2 7 5 5.4
C3 10 4 -
C4 10 3 -
a◆ dpi: days post infection
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mals euthanised seven days after infection while lung
pathology seemed to be more severe in the animals
euthanised at 10 days after infection. It has been
reported earlier that lung pathology in BRSV infection is
the consequence of immuno-pathological events rather
that direct damage of the virus to the tissues [29].
Conclusion
From the results described, it can be concluded that, a
single vaccination with an inactivated BRSV vaccine was
able to break through the maternal immunity and
induce partial protection in very young calves. It can be
speculated that the level and duration of the protection
w i l li m p r o v eo n c eas e c o n dd o s eo fv a c c i n ei sg i v e n .
Therefore under field conditions the recommended vac-
cination schedule of two doses must be administered.
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